Last reviewed · How we verify
TAK-771
TAK-771 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma.
TAK-771 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma. Used for Hepatocellular carcinoma (HCC), FGFR4-driven.
At a glance
| Generic name | TAK-771 |
|---|---|
| Also known as | Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase |
| Sponsor | Takeda |
| Drug class | FGFR4 selective inhibitor |
| Target | FGFR4 (Fibroblast Growth Factor Receptor 4) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TAK-771 selectively targets FGFR4, a receptor frequently activated in hepatocellular carcinoma through FGF19 autocrine signaling, which drives tumor cell proliferation and survival. By inhibiting FGFR4 kinase activity, the drug suppresses downstream oncogenic pathways including MAPK and PI3K/AKT signaling. This selective approach aims to provide anti-tumor activity while potentially minimizing off-target toxicities associated with pan-FGFR inhibition.
Approved indications
- Hepatocellular carcinoma (HCC), FGFR4-driven
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Abdominal pain
Key clinical trials
- A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) (PHASE3)
- A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants (PHASE3)
- A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |